Ampio pharmaceuticals announces important new research manuscript on anti-inflammatory mode of action

Englewood, colo., aug. 13, 2021 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced a preprint version of a manuscript, "lmwf5a demonstrates an anti-inflammatory mode of action and similar drug targets to dexamethasone in activated pbmc," has been posted on in review, a preprint platform hosted on research square.
AMPE Ratings Summary
AMPE Quant Ranking